Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.66 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2937820 | 1.00 | HTR3A (0.66) | HTR3AJAK3HTR2CSLC18A3SIGMAR1 | |
| SCHEMBL1707108 | 1.00 | HTR3A (0.66) | HTR3AJAK3HTR2CSLC18A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL1919231 | 0.98 | HTR3A (0.63) | HTR3AJAK3HTR2CSLC18A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL21201476 | 0.98 | HTR3A (0.63) | HTR3AJAK3HTR2CSLC18A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL29051162 | 0.98 | HTR3A (0.63) | HTR3AJAK3HTR2CSLC18A3SIGMAR1 | |
| SCHEMBL28298501 | 0.91 | HTR3A (0.56) | HTR3AJAK3HTR2CMPO | |
| SCHEMBL24127465 | 0.90 | HTR3A (0.53) | HTR3AHTR2C | |
| SCHEMBL2145333 | 0.90 | HTR3A (0.53) | HTR3AHTR2C | |
| SCHEMBL25305280 | 0.90 | HTR3A (0.53) | HTR3AHTR2C | |
| Oxalic Acid SCHEMBL3552533 | 0.89 | JAK3 (0.56) | HTR3AJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459899-B2 | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient | DIGMBIO, Inc. (KR) | 2025-11-04 | — | — | US | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| CN-111936488-B | Novel compounds for the treatment of parasitic infections | 葛兰素史克知识产权开发有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230027362-A1 | ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT | DIGMBIO. INC. (KR) | 2023-01-26 | — | — | US | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| US-11453657-B2 | Compounds for the treatment of parasitic infections | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-09-27 | — | — | US | disclosed |
| EP-3743419-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-09-14 | — | — | EP | disclosed |
| EP-4053106-A1 | ISOQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION, COMPRISING SAME AS ACTIVE INGREDIENT, FOR PREVENTION OR TREATMENT OF POLY(ADP-RIBOSE)POLYMERASE-1 (PARP-1)-ASSOCIATED DISEASE | Digmbio. Inc. (KR) | 2022-09-07 | — | — | EP | disclosed |
| CN-114929673-A | Isoquinolinone derivatives, preparation method thereof, and pharmaceutical composition for preventing or treating poly (ADP-ribose) polymerase 1(PARP-1) -related diseases comprising the same as active ingredient | 多临生物株式会社 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| CN-101420959-A | Use of 2- (purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives as adenosine A2A receptor agonists | NOVARTIS AG (CH) | 2009-04-29 | — | — | CN | disclosed |
| EP-2018381-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| WO-2008101953-A1 | COMPOUNDS OF FORMULA (I) AS SERINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| CN-101128473-A | Adenosine derivatives having a2a receptor activity | NOVARTIS AG (CH) | 2008-02-20 | — | — | CN | disclosed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007121918-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| CN-1150165-C | 1-arylsulfonyl-2-aryl-pyrrolidine derivatives for the treatment of central nervous system disorders | - | 2004-05-19 | — | — | CN | disclosed |
| CN-1345311-A | 1-arenesulfonyl-2-aryl-pyrolidine and piperidine derivatives for treatment of CNS disorders | HOFFMANN LA ROCHE (CH) | 2002-04-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | HTR3A 43/4885JAK3 1252/4885HTR2C 81/4885 |
| US-12459899-B2 | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient | PARP1, PARP2, PARP11 | HTR3A 2632/4885JAK3 4644/4885HTR2C 3550/4885 |
| US-11453657-B2 | Compounds for the treatment of parasitic infections | PIGO, SGMS2, ABCB11 | HTR3A 4645/4885JAK3 2000/4885HTR2C 4693/4885 |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | HTR3A 4363/4885JAK3 2730/4885HTR2C 4537/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | HTR3A 4363/4885JAK3 2730/4885HTR2C 4537/4885 |
| US-20230027362-A1 | ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT | PARP1, PARP2, PARP11 | HTR3A 2632/4885JAK3 4644/4885HTR2C 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.